Content about XML

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients. With a focus on improving legislative, intellectual property,regulatory, and reimbursement frameworks, the PMDxWorking Group seeks to better align the incentives connecting the research, development and commercialization of personalized medicine products.

Executive Summary

1) This report was commissioned by the Biotechnology Industry Organization (BIO).

2) This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and inventions in developed, emerging and developing economies.

3) The report provides a review and analysis of the existing body of knowledge concerning the role of IPRs more generally as well as specifically in biopharmaceutical and biotechnological innovation.

Biotechnology’s Impact on Food Ingredients

Jim Greenwood and Tom Watkins, President & CEO of Human Genome Sciences and Chair of BIO’s Board of Directors, hosted a media briefing on January 23 to share BIO’s advocacy accomplishments in 2011 and policy priorities for 2012.

6000 B.C. — Ancient writings from around 6000 B.C. indicate the Sumerians and Babylonians knew how to use microbial yeasts to make beer.

4000 B.C. — The Egyptians make leavened bread using yeast.

500 B.C. — The Chinese use filamentous fungi (mold) as an antibiotic to treat boils.

mid-1800’s — Louis Pasteur proposes that fermentation is a result of microbial activity.

With the overwhelming success of our recent Call for Sessions, next year’s BIO International Convention may be the best yet!

Companies, institutions, and organizations from around the globesubmitted more than 500 entries to host a session at the Convention. Word has quickly spread that for an organization to maximize visibility and credibility among the most influential people in the industry, becoming a session host is invaluable.

Don’t miss your chance to host a session at the 2012 BIO International Convention! With 15,000+ biotechnology professionals in attendance, a diverse audience representing 50 states and 65 countries, and representatives from the world’s top pharmaceutical companies, there is no better opportunity to gain publicity and credibility with the most influential people in the industry.

Consideration of the first genetically engineered food animals, the AquAdvantage salmon, by the U.S. Food and Drug Administration (FDA) continues.

This salmon has been genetically engineered to reach its market weight in half the time of conventionally raised salmon thus contributing to more sustainable aquaculture systems. On December 21, 2012, the FDA released the long-awaited environmental assessment (EA) of the GE AquAdvantage salmon.

The contents of the member listings on the BIO Web site may not be reproduced or used in any form without prior written permission from BIO. For more information about members, please refer to the organization's Web site. Web site links are provided below.

Eligibility to participate on BIO staff-level committees varies with each committee, but is based on one of the general four policies set forth below. Please refer to each committee to determine eligibility. Please note that committees may have additional, committee-specific eligibility requirements not listed below depending on the nature and focus of the committee (e.g., BIO's General Counsels Committee is limited to General Counsels or Senior Legal Officers of BIO member companies).

General Eligibility Policies:

The committee consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board by the Chair and approved by the Board. The committee is authorized to exercise all powers of the Full Board, except for certain powers reserved for the Full Board under BIO's Bylaws.
Staff Contact: Scott Whitaker